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Abstract 35 
Background: A subgroup of patients with common variable immunodeficiencies (CVID) 36 
responds to vaccination. The aim of the study was to try to identify predictive markers for 37 
those who developed a humoral immune response after influenza vaccination. 38 
Methods: 48 patients with CVID (29 females, 19 males, mean age 59.4 years) were 39 
vaccinated with the A(H1N1) influenza vaccine Pandemrix® and boosted after one month. 40 
Blood samples were collected prior to each vaccination and two months later. Patients with a 41 
4-fold titer increase of the hemagglutinin inhibition test (≥ 1:40) were considered responders 42 
and compared to non-responders for clinical, immunological and genetic markers. 43 
Results: Eight (16.7%) patients responded to the vaccination. A significantly higher 44 
proportion of the responders, who showed a Euroclass SmB-Trnorm21norm profile (p=0.03) with 45 
a post-germinal center B cell pattern (p=0.04) in blood, suffered from enteropathies (p=0.04) 46 
as compared to non-responders. Bronchiectasis on the other hand, was exclusively found 47 
among non-responders (n=7), as was autoimmune cytopenia (n=5). Non-responders with a 48 
Euroclass SmB-21lowTrnorm profile (p=0.02), had a significantly higher prevalence of 49 
progressive antibody deficiency (p=0.048) and, at diagnosis, a higher mean serum IgM level 50 
(p=0.03), a lower mean serum IgG1 level (p=0.007), an expansion of absolute counts of 51 
cytotoxic CD8+ T-cells (p=0.033) and an increased proportion of memory CD8+ T-cells 52 
(p=0.044) in blood. CVID associated HLA markers were not detected in non-responders 53 
(p=0.03). 54 
Conclusion: About one-fifth of the CVID patients achieved protective antibody levels after 55 
A(H1N1) vaccination and selected clinical and immunological markers were identified that 56 
may predict a positive outcome of influenza vaccination.  57 
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Key messages: 58 
• A subgroup of patients with CVID develops a humoral immunological response from 59 
influenza vaccination. 60 
• Selected clinical and immunological markers may help to identify a possible positive 61 
influenza vaccination outcome and are enteropathy, Euroclass SmB-Trnorm21norm and 62 
post-germinal center B-cell pattern. 63 
• HLA CVID genetic predisposing markers, pronounced IL-12 production and Th1 64 
polarity were observed only in non-responders. 65 
• Despite the fact that not all patients with CVID will develop protective antibody levels 66 
after influenza vaccination it is concluded that they should be offered this prophylactic 67 
measure due to the potential severity of influenza and risk for bacterial complications.  68 
 69 
Capsule Summary: One-fifth of the patients with CVID vaccinated against pandemic 70 
influenza A(H1N1) converted to a ≥ 1:40 titer of specific antibodies against the antigen and 71 
selected clinical and immunological predictive markers were identified in this subgroup. 72 
 73 
Keywords: Common variable immunodeficiency, CVID, specific antibody deficiency, 74 
vaccination, influenza, pandemic influenza, immune response, A(H1N1), Pandemrix 75 
Abbreviations: 76 
CVID: Common variable immunodeficiency 77 
DNA: Deoxyribonucleic acid 78 
ELISA: Enzyme-linked immunosorbent assay  79 
HA: Hemagglutinin 80 
HI: Haemagglutination inhibition 81 
HLA: Human leukocyte antigen 82 
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Igs: Immunoglobulins 83 
IFN-γ: Interferon gamma 84 
IL: Interleukin  85 
PBS: Phosphate-buffered saline 86 
PCR: Polymerase chain reaction 87 
PID: Primary immunodeficiency disorder 88 
PHA: Phytohemagglutinin 89 
RDE: Receptor-destroying enzymes 90 
WHO: World Health Organization  91 
92 
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Introduction 93 
Common variable immunodeficiency (CVID) is a heterogeneous primary 94 
immunodeficiency disorder (PID) characterized by low serum concentrations of 95 
immunoglobulins (Igs) and impaired specific antibody production.1-3 Specific antibody 96 
deficiency is a diagnostic criterion in most of the standard clinical guidelines and constitutes 97 
the absence of natural Igs (e.g. isohemagglutinins) or poor response to novel protein or 98 
polysaccharide antigens (e.g. in vaccines).2, 4, 5  99 
Approximately 10-20% of clinically diagnosed patients with CVID have a residual 100 
response to vaccination against protein antigens and, to a lesser extent, against polysaccharide 101 
antigens.6-12 The heterogeneity in specific antibody defects in CVID patients may be due to 102 
the association of this complex disease with several different genetic defects.13, 14 Although it 103 
is uncertain whether vaccination with killed/inactivated vaccines will protect an individual 104 
with CVID, the use of these vaccines is nevertheless recommended for diagnostic purposes.10, 105 
15 Moreover, the use of killed/inactivated vaccines to patients with PID is indeed 106 
recommended to follow the same schemes as in general populations.16 107 
Current evidence suggests that a subgroup of patients with CVID is not only capable of 108 
re-stimulation in vitro for production of class-switched Igs but may show residual antibody 109 
production in vivo.17-19 Characterization of this subgroup of patients regarding their clinical, 110 
immunological and genetic profile could potentially help developing targeted therapy for 111 
these patients18, 20 and provide evidence-based advises regarding administering influenza 112 
vaccine to patients with CVID. 113 
To our knowledge, the immunological response to the same antigen as used in the current 114 
study - A(H1N1) pandemic influenza vaccine (antigen X179a 2009, Pandemrix®) - has so far 115 
only been investigated in three patients with CVID and one patient with X-linked 116 
agammaglobulinemia in a 3-months long follow-up study.19 Two of the patients with CVID 117 
responded to the vaccination by a >4-fold rise in haemagglutination inhibition (HI) antibodies 118 
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and all three showed a Th1-cell response. It was concluded that some patients with CVID 119 
might produce an influenza-specific humoral immune response, but that this should be 120 
confirmed in larger studies.  121 
The aim of the study was to try to identify clinical, immunological and genetic predictive 122 
markers for those patients with CVID who developed a humoral immune response after 123 
influenza vaccination. This was performed by investigating to what extent a group of patients 124 
with CVID responded to vaccination by producing protective antibodies against the 125 
glycopeptide pandemic influenza A(H1N1) antigen.   126 
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Material and methods 127 
The present study had a prospective design, monitoring patients with CVID before and up to 128 
one year after vaccination with the pandemic influenza A(H1N1) vaccine (Pandemrix®, 129 
GlaxoSmithKline, Belgium). 130 
 131 
Patients  132 
Patients with CVID cared for and receiving Ig replacement therapy at the 133 
Immunodeficiency Unit at the Karolinska University Hospital in Stockholm, Sweden, and 134 
who had not already been vaccinated against the A(H1N1) pandemic virus were invited to 135 
participate in the study carried out during 2010-2011. None of the patients used any steroids 136 
or any other immuno-suppressive therapy during the study period and 3 months prior to study 137 
start. All patients had been diagnosed as having CVID based on the diagnostic criteria 138 
established by the European Society for Immunodeficiencies 139 
(http://esid.org/WorkingParties/Registry/Diagnosis-criteria) and the American Academy of 140 
Allergy, Asthma and Immunology practice parameter for the diagnosis and management of 141 
PID.4, 21 Before study start, all patients were re-evaluated for fulfilling the diagnostic criteria 142 
of CVID and secondary causes of dysgammaglobulinemia were ruled out.22 None of the 143 
invited patients presented with protein losing enteropathy, nor with pre-study protective 144 
A(H1N1) pandemic virus antibody levels (≥1:40 titer). 145 
Fifty-seven patients gave their informed consent and volunteered to participate in the 146 
study by receiving the first dose of the vaccine. Nine patients (five women and four men, 147 
mean age 48.8±20.3) dropped out of the study; seven at the first follow-up visit and two 148 
patients at the second follow-up visit. Totally 48 patients (60.4% females) participated in all 149 
appointments and were included in the final vaccine response analyses. Forty-seven of the 150 
patients received regular weekly subcutaneous (minimum 100 mg/kg/week) and one patient 151 
received monthly intravenous (400 mg/kg/month) Ig replacement therapy before and during 152 
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the entire study period. Different brands were used but each patient received the same brand 153 
and batch of Ig at least three months before and at least until the last blood sampling. 154 
An evaluation document was used to summarize the demographic information of each 155 
patient including age at diagnosis, family history and history of previous vaccinations shown 156 
as specific antibody responses, and clinical, immunological and genetic data.  157 
 158 
Study overview  159 
The A(H1N1) pandemic influenza vaccine Pandemrix®, a monovalent X179a 2009 160 
vaccine, was injected intramuscularly at study start and boosted once after one month. In each 161 
vaccination dose, 3.75 µg of hemagglutinin (HA) of the X179a antigen was administered. At 162 
study start, concentrations of total IgG, IgG subclasses, IgA and IgM were determined in fresh 163 
serum samples taken immediately prior to the next Ig substitution. Specific antibody titers for 164 
antibodies against the pandemic influenza A(H1N1) antigen were measured in samples 165 
collected prior to the first and the second vaccination and also two months after the second 166 
dose. Follow-up visits due to the vaccine study were scheduled for the patients at regular 167 
intervals until one year after study start for the recording of any influenza-like symptoms 168 
and/or incidental side effects of the vaccination.  169 
 170 
Investigation and definition of vaccination response 171 
One volume of serum was treated with four volumes of neuraminidase receptor 172 
destroying enzyme (RDE, Seiken, Japan) in phosphate-buffered saline (PBS) at 37°C 173 
overnight before inactivation at 56°C for 30 minutes to prevent non-specific inhibition. Serial 174 
two-fold dilutions of RDE treated sera were then incubated with eight haemagglutinating 175 
units of the X179a pandemic influenza A(H1N1) antigens for one hour, followed by the 176 
addition of 0.7% ([volume of solute/volume of solution] ×100%) turkey erythrocytes. After 177 
30 minutes of incubation, the HA inhibition titers were read as the reciprocal of the highest 178 
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dilution at which 50% HA was inhibited. Each serum sample was run in duplicate in two 179 
independent experiments and the titers are presented as a mean of these two experiments for 180 
each patient.  181 
A positive response to the pandemic influenza A(H1N1) antigen was defined as a 4-fold 182 
titer increase of the HA inhibition test (≥ 1:40).23 Patients with such increase are hereinafter 183 
referred to as responders.  184 
 185 
Clinical and immunological phenotyping and immunological assays 186 
The clinical phenotyping of the 48 patients was based on the suggested division into 187 
distinct clinical phenotypes by Chapel et al.24 and included patients with infections but no 188 
other disease-related complications or patients with infections and autoimmunity, infections 189 
and enteropathy and/or infections and polyclonal lymphocytic infiltration. Patients with ≥3 190 
clinical findings were classified as overlapping phenotypes. Clinical data were collected from 191 
the medical and nursing records and covered the time from diagnosis to the study start. 192 
Thirty-eight of the patients had previously been classified based on two main 193 
classifications for B-cell subsets including the Paris, Freiburg, EUROclass25 and the B-cell 194 
pattern classification.26 In 27 of the patients, ionizing radiation sensitivity assays had 195 
previously been performed on primary fibroblasts irradiated with different doses and serial 196 
dilutions.27 This is a method used for classification of patients with CVID and defective DNA 197 
repair machinery required for variable (V), diversity (D) and joining (J) genes rearrangement 198 
and class-switch recombination.28-31 199 
Peripheral blood monoclonal cells from all 48 patients were stimulated for 48 hours with 200 
phytohemagglutinin (PHA) and cytokine production of interferon gamma (IFN-γ), interleukin 201 
2 (IL-2), IL-5, IL-10 and IL-12 were measured by enzyme-linked immunosorbent assay 202 
(ELISA) using a method described previously.32  203 
 204 
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Screening of positional candidate genetic markers  205 
HLA-A, -B, -DQ and -DR alleles were determined using low-resolution DNA-based 206 
typing (polymerase chain reaction [PCR]/sequence specific oligonucleotide probe).33 The 207 
PCR amplification of tumour necrosis factor receptor superfamily member 13 B and C 208 
(TNFRSF13B and TNFRSF13C) and their Sanger sequencing were performed using primers 209 
and conditions as previously described.34 Of note, selected monogenic forms of PID were 210 
excluded in studied patients according to the CVID diagnostic criteria using a targeted gene 211 
panel sequencing (covering 260 known monogenic diseases) including BTK, BLNK, CD79A, 212 
CD79B, IGHM, IGLL1, TCF3, CD19, CD20, CD21, CD81, AICDA, UNG, INO80, MSH6, 213 
CARD11, NFKB1, NFKB2, PI3KCD, PIK3R1, PTEN, DOCK2, IKAROS, IRF2BP2, MOGS, 214 
TWEAK, IL21, IL21R, LRBA and CTLA4 genes. Moreover, whole exome sequencing in 17 215 
patients were also performed, but neither non-responders nor responders had a confirmed 216 
candidate monogenic disease.  217 
 218 
Ethical considerations 219 
The World Health Organization declared in June 2009 that the outbreak of A(H1N1) 220 
influenza fulfilled the criteria of a pandemic situation. As a consequence, the National Board 221 
of Health and Welfare in Sweden recommended the general population to be vaccinated and 222 
certain risk groups, including individuals with an impaired immune system, to be prioritized. 223 
The pandemic influenza A(H1N1) vaccine had not previously been used in a mass vaccination 224 
situation, but the potential severity of the disease motivated patients with CVID to be offered 225 
the new vaccine. 226 
Based on the Ethical Review of Research Involving Humans35 the vaccination including 227 
blood sampling and follow-up schedule were approved by the regional Ethical Committee 228 
(approval number 2009/1646-31-3). The patients were given oral and written information 229 
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about the study. The principle of volunteering was emphasized and informed written consent 230 
to participate including a one-year follow-up was obtained from all patients.  231 
 232 
Statistical analyses 233 
Statistical analyses were performed using SPSS (version 21.0.0, Statistics software, 234 
SPSS, Chicago, Illinois) and R statistical systems (version 3.4.1., R Foundation for Statistical 235 
Computing, Vienna, Austria). The one-sample Kolmogorov-Smirnov test was applied to 236 
estimate whether the data distribution was normal and based on the findings of this evaluation 237 
independent T-test (in normal distributions) and Mann-Whitney U test (in skewed 238 
distributions) were used to compare continuous variables between responders and non-239 
responders. Differences in categorical variables between responders and non-responders were 240 
examined using χ2 tests and Fisher's exact tests (the latter when variables had a low 241 
frequency). Pearson’s correlation coefficient analysis was used to investigate the relationship 242 
between specific antibody responses to different antigens. A p-value of 0.05 or less was 243 
considered statistically significant.    244 
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Results  245 
Three months after the first vaccine dose and two months after the second dose, eight 246 
(16.7%) patients had reached a ≥1:40 titer of specific antibodies against the pandemic 247 
influenza A(H1N1) antigen (responders) whereas the remaining 40 patients (83.3%) were 248 
considered as non-responders. The production of specific antibodies against the antigen is 249 
depicted in Figure 1. Four out of eight responders reached protective levels already after the 250 
first vaccine dose. Comparing the four early responders with the four late responders, no 251 
significant differences could be found between their current age (57.0±14.7 vs. 54.2±11.7 252 
years) or age at CVID diagnosis (41.5±10.0 vs. 39±16.8 years). 253 
During the study period, none of the patients showed any clinical symptoms of having 254 
been infected with the ongoing pandemic influenza A(H1N1) and during the one-year follow-255 
up period, no influenza-like symptoms and/or negative side-effects other than local reactions 256 
on the injection sites were reported. 257 
Table 1 summarizes the demographic and essential immunological data of responders 258 
and non-responders. Response to the A(H1N1) pandemic vaccine was independent of the 259 
gender of the patients. There were also no significant differences in the mean age at diagnosis, 260 
mean age at study start, mean years from onset of infections to diagnosis or the mean follow-261 
up time after the CVID diagnosis between responders and non-responders, respectively. Nine 262 
patients had a familiar form of CVID, all belonging to the non-responder group. In the total 263 
group, 14 individuals (29.1%) had evolved from an IgA deficiency (n=12) and/or IgG 264 
subclass deficiency (n=2) to a CVID diagnosis during the course of their disease. All these 14 265 
patients were non-responders constituting 35.0% of this group (p=0.048, compared to absence 266 
of this progressive PID form in responders) (Table 1). 267 
Regarding the Ig replacement therapy there was no difference in the distribution of 268 
different Ig brands used between responders and non-responders (data not shown). 269 
 270 
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Clinical phenotyping  271 
Before diagnosis, all 48 patients had experienced recurrent upper respiratory tract 272 
infections and 44 had also been diagnosed as recurrently suffer from lower respiratory tract 273 
infections (bronchitis and/or pneumonia). Clinical phenotyping of the 48 patients revealed 274 
that 14 (29.2%) of them presented with infections without any other disease-related 275 
complications, 14 (29.2%) by infections and autoimmunity, four (8.3%) by infections and 276 
enteropathy, and three (6.2%) by infections and polyclonal lymphocytic infiltration. Thirteen 277 
patients (27.1%) also manifested overlapping phenotypes (Figure 2, Table S2).  278 
When dividing the clinical phenotyping between responders and non-responders the 279 
proportion of patients with infections without any other disease-related complications was 280 
12.5% among the responders and 32.5% among the non-responders (p=0.12) (Figure 2, 281 
Table S2). Lower respiratory tract infections were documented in five responders (62.5%) 282 
and in 33 non-responders (82.5%, p=0.20). None of the responders showed signs of 283 
bronchiectasis, while seven non-responders (17.5%; p=0.10) suffered from this condition. 284 
The phenotype infections and enteropathy was significantly higher in responders (50% 285 
vs. 0%, p<0.001). Although infections and autoimmunity was present in about the same 286 
proportion in both groups (25% in responders and 30% in non-responders, n.s.) (Figure 2, 287 
Table S2), autoimmune cytopenia was exclusively observed among the non-responders (n=5).  288 
Malignancies were recorded in 12 patients (30%) in non-responders, mainly due to 289 
thymoma and lymphoma and in two patients (25%) among the responders (one breast cancer 290 
and one colon cancer) (p=0.3882) (Table S2). 291 
No significant difference was observed regarding the proportion of patients with IgE 292 
mediated atopic disorders: four responders (50%) and nine non-responders (22.5%, p=0.12) 293 
(Table S2).  294 
 295 
 296 
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Immunological phenotyping and classification  297 
At the time of the CVID diagnosis, a significantly higher mean serum level of IgM 298 
(34.8±29.6 vs. 17.0±16.0 mg/dl; p=0.03) and a significantly lower mean serum level of IgG1 299 
(122.4±96.3 vs. 219.2±198.3 mg/dl; p=0.007) were noted in non-responders as compared to 300 
responders. Lymphocyte subset analyses showed an expansion of absolute counts of cytotoxic 301 
T-cells (p=0.033) as well as an increased proportion of memory CD8+ T-cells (p=0.044) in the 302 
non-responders as compared to the responders. Furthermore, there was a tendency of a higher 303 
number of NK-cells among the non-responders as compared to the responders (p=0.06). There 304 
was no significant difference between responders and non-responders regarding absolute B-305 
cell counts, although the non-responders presented a decreased number of plasmablast and an 306 
increased CD21low percentage (p=0.007 and p=0.041, respectively) (Table 2). 307 
Radiosensitivity was only documented in the group of non-responders (4/20 tested non-308 
responders, 20%, vs. 0/7 tested responders, p=0.09). 309 
Although a positive correlation was observed in responders with increment in the level of 310 
protective antibodies after the vaccination with the pandemic influenza A(H1N1) antigen 311 
regarding the production of other specific antibodies against protein and polysaccharide 312 
antigens (r=0.75, p=0.08), no statistically significant differences were found between 313 
responders and non-responders. Details of the humoral immune response to other antigens are 314 
presented in Table S1. 315 
Immunological classification of the patients revealed that the most frequent immune 316 
profile in the responders was Euroclass SmB-Trnorm21norm (p=0.03) and post-germinal center 317 
B-cell pattern (normal naïve, transitional, marginal and memory B-cell subsets) (p=0.04) as 318 
compared to the non-responders, whereas the most frequent immune profile of non-319 
responders was Euroclass SmB-21lowTrnorm (p=0.02 compared to the responders) (Figure 3). 320 
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The PHA induced cytokine production in vitro in responders and non-responders are 321 
presented in Figure 4. A significant difference was found in mean IL-12 levels; in non-322 
responders 1,081.2±651.3 pg/ml and for responders 283.3±256.5 pg/ml (p=0.007).  323 
 324 
Genetic markers associated with CVID and pandemic influenza A(H1N1) antibody 325 
production  326 
Four patients with TNFRSF13B (10%) and one patient with TNFRSF13C (2.5%) CVID 327 
susceptibility variants were found among the non-responders while only WT TNFRSF13 328 
genes were identified among the responders (12.5% vs 0%, p=0.38). HLA markers associated 329 
with CVID were detected in 16/40 (40%) of the non-responders; HLA-DR3-DQ2 in six 330 
patients, HLA-A1-B8 in six patients and HLA-A2-B44 in four patients. HLA markers 331 
associated with CVID were not found in any of the responders (40% vs 0%, p=0.03).   332 
Unmarked 
17 
 
Discussion 333 
The outbreak of the pandemic influenza A(H1N1) and the recommendation to 334 
specifically vaccinate individuals with an impaired immune system did not only stress the 335 
immediate medical need to offer this new vaccine with a A(H1N1) clade selected by WHO to 336 
patients with CVID, but it also opened up a possibility for a scientific evaluation of the 337 
vaccination in this group of individuals. The background to the study was the perpetual 338 
discussion whether patients with CVID should routinely be offered vaccination against 339 
seasonal influenza. Only our study and the study by Pedersen et al.19 have presented data from 340 
the use of the specific antigen X179a to individuals with CVID. Our study was designed as an 341 
evaluation within the group of patients and therefore no healthy controls were included. 342 
However, it has been shown that between 67-98.3% of healthy adults produce protective 343 
levels of antibodies against the influenza A(H1N1) vaccine Pandemrix® 21days after a single 344 
dose of 3.75 µg of the vaccine. 36, 37 345 
Cross-reactive A(H1N1) antibodies are present in healthy populations38 and 346 
consequently, antibodies against the pandemic influenza A(H1N1) antigen may be present in 347 
Ig preparations.39 All participants in the study were therefore tested for pre-excising A(H1N1) 348 
antibodies before entering the study. One 73-year old male had a HA inhibition titer of 1:10 at 349 
the study start but this patient did not respond to the vaccination. All patients continued with 350 
the same brand and batch of Ig during the study period. 351 
The WHO declaration in 2009 of a pandemic situation in 74 countries and territories 352 
rapidly led to a demand for the vaccine that was greater than the supply. On a European level 353 
it was considered important to offer the vaccine rapidly to as many individuals as possible. 354 
For this reason it was decided by the authorities to start the vaccination campaign with an 355 
antigen dose of 3.75 µg to the entire population but immunodeficient patients were to be 356 
offered a second dose after one month. It has later been shown that a single dose of 3.75 µg of 357 
Pandemrix® with the antigen X179a brings about immunity to protective level in healthy 358 
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adults and elderly.40 In the study by Pedersen et al. about the immunological response to the 359 
antigen X179a in CVID19, the intention was to give two doses of 3.75 µg to three patients 360 
with CVID but the patients were accidentally given a double dose of Pandemrix® at study 361 
start. Two of the patients were then given a second dose of 3.75 µg after three weeks whilst 362 
the third patient declined being given the second dose. The two patients receiving two doses 363 
(7.5 µg + 3.75 µg) responded with a >4-fold humoral response while the patient receiving one 364 
dose (7.5 µg) had a HI titer below ≥1:40. In our study, four of the responders developed 365 
protective levels of antibodies against the X179a antigen already after one dose of 3.75 µg, 366 
while the four others needed two doses to produce protective levels of antibodies (Figure 1). 367 
The four early responders were not older at diagnosis or study start than the four late 368 
responders, which could have explained the result as older patients might have been in contact 369 
with cross-reactive antigens earlier. Based on the current study and the study by Pedersen et 370 
al.19, it seems reasonable to assume that two doses of 3.75 µg of the antigen X179a would be 371 
required to obtain humoral immunity in patients with CVID. Whether these patients should be 372 
offered one or two doses of inactivated seasonal influenza vaccine has never been addressed 373 
in the four groups of patients with CVID where the outcome of this type of vaccine has been 374 
investigated9, 17, 41, 42 and any answer to this question is therefore not available. However, Eibl 375 
& Wolf16 suggest that the primary immunization of inactivated influenza vaccine should 376 
follow the same scheme as for healthy individuals, but that more frequent booster 377 
immunizations might be necessary depending on the assessment of vaccination response in 378 
PID. 379 
In the influenza, polysaccharide or protein vaccine studies that have been conducted in 380 
patients with CVID7, 9, 19, 41-44 they have shown more frequent and earlier decline in antibody 381 
responses against polysaccharides compared to proteins, suggesting a preservation of T cell-382 
dependent specific antibody response in a subgroup of patients.7, 19, 43 In a previous study, 383 
Zhan et al.41 reported generation of specific IgG-secreting memory B cells post seasonal 384 
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influenza vaccines in 50% of the studied CVID patients. In our study, we found that about 385 
one-fifth (16.7%) of the patients responded by producing protective levels of antibodies 386 
against the pandemic influenza A(H1N1) antigen. Consistent with other reports, we also 387 
observed a functional classification of CVID patients, according to the level of the response to 388 
the vaccine.43, 45  389 
There are to date no studies regarding the clinical phenotypes of patients who seroconvert 390 
or not after influenza vaccination.46 The finding among the responders of a significantly 391 
higher proportion of enteropathies, a phenotype that usually presents due to increased 392 
apoptotic bodies in the gastrointestinal crypts47, may suggest that the immunological 393 
phenotype of the responders with normal B cell subsets could be a result of an increased 394 
apoptosis of the long-term plasmacells. In line with this notion these patients can produce 395 
normal antibodies against specific antigens during a short-term, but these antibody-producing 396 
plasmacells subsequently disappear. The increased susceptibility to apoptosis in the 397 
gastrointestinal crypts could be a trigger of chronic inflammation. Regarding the severe lower 398 
respiratory tract infections and the bronchiectasis among the non-responders it appears that 399 
the non-responders are less likely to mount an immune response against bacteria and 400 
consequently an effective elimination in the lower respiratory tract, resulting in persistent 401 
tissue damage in the lungs. 402 
The capability to respond to certain vaccines in vivo, strongly suggest that some patients 403 
with CVID can produce class-switched isotypes, as has been shown by cytokine stimulation 404 
in vitro.48 Although CD27+ IgD−isotype-switched memory B cells are generally reduced in 405 
CVID patients49, our findings confirm that responders had a higher level of plasmablasts and 406 
lower counts of CD21low B cells (compatible with a Euroclass SmB-Trnorm21norm and post-407 
germinal center B-cell pattern). In contrast, we found that the non-responders at diagnosis 408 
presented with lower mean serum level of IgG1 and a higher mean serum level of IgM, 409 
highlighting a severe defective class switching recombination in this group of patients. 410 
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Moreover, radiosensitivity was only found in non-responders but this test was performed only 411 
in 27 patients and the difference was not statically significant. These findings emphasize the 412 
role of the class-switching capability for developing a vaccine response. In two studies by 413 
Goldacker et al.7 and Chovancova et al.13, respectively, they presented B cell subset analysis; 414 
both reported that group II of the Freiburg classification or the EUROclass group smB+, 415 
which represent patients with CVID with nearly normal numbers of class-switched memory B 416 
cells, constitutes patient with measurable antibody responses. 417 
Stimulating peripheral blood mononuclear cells with PHA enhanced the production of IL-418 
12 at significantly higher mean level in non-responders as compared to responders, suggesting 419 
a significant immune regulation in this group toward activation of cellular immunity. Up-420 
regulation of the IL-12 as an initial factor in a subgroup of patients with CVID skews the 421 
immune response away from Ig production towards a polarized Th1-type chronic 422 
inflammation.50, 51 Increased expression of the IL-12β1 receptor has also been reported in 423 
these patients.52 Although the IFN-γ level, another marker of Th1-response, did not differ 424 
between the two groups, Ig replacement may alter the serum pattern of this cytokine but not 425 
the IL-12 level.53 Failure of an immune deviation from a systemic Th1 response to a Th2 426 
immune response may explain the mechanism responsible for the numerically lower 427 
proportion of IgE mediated atopic diseases observed in the non-responders as compared to 428 
responders.54  429 
Humoral response against influenza vaccine has been shown to be the major source of 430 
protection against infections and individuals with annual injections have a broader antibody 431 
recognition profile after pathogenic confrontation.55 However, influenza-specific CD8+ T 432 
cells can be generated after vaccination targeted to conserved viral proteins (nucleoprotein 433 
and the matrix protein) to provide heterosubtypic immunity. Since long-term annual 434 
vaccination in the presence of normal humoral immunity may interfere the induction of 435 
heterosubtypic immunity, it can be hypothesized that virus-specific CD8+ T cell responses are 436 
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more pronounced in patients with antibody deficiency.56 As the current study only focused on 437 
humoral immunity, further evaluation of the cellular immunity in these patients may be of 438 
considerable interest. 439 
The presence of the familiar form of CVID only in non-responders, taken together with 440 
the finding of predisposing HLA and non-HLA factors, suggest a strong association of CVID 441 
pathogenetic in this group of patients.57 Moreover, the progressive primary antibody 442 
deficiency was exclusively found in the non-responders, a phenomenon that has previously 443 
been linked to genetic susceptibility markers in patients with CVID, in particular HLA A1, 444 
B8, DR3 and DQ2.58, 59 Investigation of non-genetic etiologies among responders should be 445 
prioritized, including epigenome and microbiome assays. The essential role of specific HLA 446 
haplotype in response to vaccine has been investigated also in healthy individuals; particularly 447 
CVID HLA susceptibility markers such as DQ2-DR3 phenotypes have been linked with non-448 
responsiveness to hepatitis B antigen in vaccine in the normal population.60, 61 Specific 449 
antibody response to vaccines has also been investigated in patients with TNFRSF13B 450 
mutated alleles and transmembrane activator and CAML interactor (TACI) knockout mice due 451 
to the role of TACI in signaling for induction of Ig class switching. Most of the animal studies 452 
have showed consistent defective responses to vaccination with T independent antigens.62 453 
However, humans with heterozygous TNFRSF13B mutations show a wide range of ability to 454 
respond to vaccine from absent to some antibody production63, 64 even within the same family 455 
with same mutation65, suggesting a presence of other genetic modifier rather than TACI. 456 
To summarize, we identified protective increment in the level of antibodies against the 457 
pandemic influenza A(H1N1) antigen in eight (16.7%) patients of our study population 458 
including totally 48 individuals. This is to date the largest study performed investigating 459 
influenza vaccine response in patients with CVID. We found that a positive outcome of the 460 
influenza vaccination might be expected in patients with certain identified specific B cell 461 
patterns. The responders were sporadic cases without genetic susceptibility markers, but with 462 
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normal class switching recombination and DNA repair machinery. Therefore they could still 463 
produce residual specific antibodies against the current antigen, and they presented with low 464 
rate of severe lower respiratory tract infections and no infectious complications such as 465 
bronchiectasis. Instead, these patients more often presented with enteropathy. 466 
Predictive markers for patients with CVID who will respond to influenza vaccine were 467 
found to be enteropathy, Euroclass SmB-Trnorm21norm and post-germinal center B-cell pattern. 468 
Despite the fact that not all patients with CVID developed protective antibody levels after two 469 
doses of the vaccine, it is concluded that patients with CVID should be offered vaccination 470 
also against seasonal influenza9, 16, 17, 42, 46 due to the potential severity of the infection and risk 471 
for bacterial complications. Adverse events are not a major issue and inactivated influenza 472 
vaccine can safely be given to patients with CVID.   473 
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Table 1- Demographic data of 48 patients with CVID including eight responders (≥1:40 titer) and 40 699 
non-responders to the A(H1N1) pandemic influenza vaccine.  700 
 701 
a Progression of other types of primary antibody deficiency including IgA deficiency and IgG subclass 702 
deficiency to CVID. 703 
* p values <0.05 were regarded signiﬁcant and are bolded  704 
Parameters Total group Responders Non-responders p-value* 
Number 48 8 40 - 
Gender (F/M) 29/19 5/3 24/16 0.62 
Mean age at diagnosis of CVID (years) 44.2±18.0 40.5±15.4 44.9±18.5 0.26 
Mean age at study start (years) 57.7±14.9 54.3±16.2 58.3±17.4 0.60 
Mean years from onset of infections to 
diagnosis (years) 
12.9±10.6 9.4±8.2 13.6±9.7 0.44 
Mean follow-up after diagnosis (years) 13.4±8.8 13.8±8.0 13.4±9.1 0.72 
Familial cases (%) 9(18.7) 0 9(22.5) 0.16 
Progressive primary antibodya 
deficiency (%) 
14(29.1) 0 14(35) 0.048 
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Table 2- Immunologic data of 48 patients with CVID at diagnosis including 8 responders and 40 non-705 
responders to A(H1N1) pandemic vaccine. 706 
Parameters Normal range Total CVID Responders Non-
responders 
p-value* 
IgM (mg/dl) 50-370 31.7±9.7 17.0±16.0 34.8±29.6 0.03 
IgA (mg/dl) 80-380 9.2±8.4 9.5±8.4 9.2±7.0 0.76 
IgG (mg/dl) 600-1500 209.2±173.4 243.7±206.1 201.7±167.8 0.20 
IgG1 (mg/dl) 280-800 141.3±125.7 219.2±198.3 122.4±96.3 0.007 
IgG2 (mg/dl) 115-570 49.3±37.0 48.0±36.1 49.7±37.0 0.74 
IgG3 (mg/dl) 24-125 19.9±18.1 19.3±16.5 22.3±21.4 0.30 
White Blood cells (cell/ul) 3500-8800 5828.5±2395.2 5971.4±1729.8 5791.4±2565.9 0.49 
Lymphocyte (cell/ul) 1130-2720 1364.4±607.2 1237.3±318.0 1397.4±662.6 0.10 
T cells (cell/ul) 780-2070 1126.6±489.8 1032.8±264.8 1150.9±534.1 0.056 
CD4+ T cells (cell/ul) 490-1340 516.4±244.3 504.2±187.6 519.6±260.0 0.46 
Naive CD4 (% of CD4+ T cells) 11-35 13.0±8.0 16.1±9.5 12.1±7.4 0.24 
Memory CD4 (% of CD4+ T cells) 31-74 70.4±14.8 70.5±14.5 70.4±15.2 0.8 
CD8+ T cells (cell/ul) 190-800 625.4±342.3 530.5±230.4 650.0±365.2 0.033 
Naive CD8 (% of CD8+ T cells) 27-69 35.4±12.1 32.8±14.0 36.1±11.7 0.42 
Memory CD8 (% of CD8+ T cells) 12-50 35.5±2.0 33.2±9.7 43.1±16.4 0.044 
CD4:CD8 1-4 1.1±0.9 1.0±0.4 1.1±1.0 0.28 
NK cells (cell/ul) 70-420 94.1±61.6 78.5±23.4 98.1±67.9 0.06 
B cell (cell/ul) 90-400  123.7±94.9 114.2±91.2 126.2±94.5 0.56 
Naïve B (% of CD19+ T cells) 47-84 70.2±21.4 71.6±17.6 69.7±22.8 0.72 
Transitional B (% of CD19+ T 
cells) 
0-1 4.3±3.6 4.2±4.0 4.4±3.9 0.48 
Natural memory B (% of CD19+ 
T cells) 
6-29 21.12±17.4 18.9±11.7 22.0±19.0 0.28 
Switched memory B (% of CD19+ 
T cells) 
9-29 6.4±6.0 8.0±7.8 5.9±5.0 0.41 
Plasmablast (% of CD19+ T cells) 0-3.2 0.06±0.01 0.1±0.02 0.04±0.03 0.007 
CD21 low B (% of CD19+ T cells) 0.7-10 15.0±10.9 8.5±4.6 17.2±11.6 0.041 
* p values <0.05 were regarded signiﬁcant and are bolded 707 
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Figure legends 1 
Figure 1- Specific antibody response against A(H1N1) pandemic influenza vaccination after 1 and 3 2 
months in 48 patients with CVID. 3 
Figure 2- Clinical phenotyping of 48 patients with CVID including 8 responders and 40 non-4 
responders to A(H1N1) pandemic influenza vaccine. During the course of the disease, all patients 5 
presented with the phenotype infections. Thus, the patients had at least the phenotype infections (here 6 
presented as “No disease-related complications”) or the phenotype infections together with one or 7 
more of the phenotypes in the figure (for detail of clinical phenotyping see Table S2).  PLI: polyclonal 8 
lymphocytic infiltration.   9 
Figure 3- Immunological phenotyping in percentage of 48 patients with CVID including 8 responders 10 
and 40 non-responders to A(H1N1) influenza pandemic vaccine and classification according to the A. 11 
Paris classification (0: low switch memory[SM] and low total memory [M], 1: low SM and normal M, 12 
2: normal SM and normal M), B. Freiburg classification (1a: low SM and increased CD21low, 1b: low 13 
SM and normal CD21low, 2: normal SM and normal M), C. Euroclass classification (according to SM, 14 
CD21low and Transitional [Tr] B cells) and D. B cell pattern classification (P1:low Tr and low M, P2: 15 
low naive and low M, P3: low marginal zone and lowM, P4: lowM and P5: normal). 16 
Figure 4- Cytokine production of interferon gamma (IFN-γ), interleukin 2 (IL-2), IL-12, IL-5 and IL-17 
10 in 48 patients with CVID, including 8 responders (R) and 40 non-responders (NR) to A(H1N1) 18 
pandemic influenza vaccine after phytohemagglutinin stimulation. 19 
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Table S1- Specific antibody response to protein and polysaccharides antigens a 7 
Parameters Total CVID 
 
Numbers (%) 
Responders to 
Pandemrix® 
Numbers (%) 
Non-responders 
to Pandemrix® 
Numbers (%) 
p-value 
Diphtheria Ab (normal/total tested)  11/27(40.7) 2/5(40) 9/22(40.9) 1.0 
Tetanus Ab (normal/total tested) 13/34(38.2) 3/5(60) 10/29(34.4) 0.34 
CMV Ab (normal/total tested) 6/17(35.2) 1/4(25) 5/13(38.4) 1.0 
MCV Ab (normal/total tested) 2/10(20) 0/1(0) 2/9(22.2) 1.0 
Teichoic acid Ab (normal/total tested) 9/16(56.2) 1/3(33.3) 8/13(61.5) 0.55 
Hib Ab (normal/total tested) 6/11(54.5) 1/1(100) 5/10(50) 1.0 
Pneumococcus Ab (normal/total tested)  1/9(11.1) 1/1(100) 0/8(0) 0.11 
PPS6 Ab (normal/total tested) 7/16(43.7) 1/3(33.3) 6/13(23) 1.0 
PPSV23 Ab (normal/total tested) 4b/9(44.4) 1/3(33.3) 3/6(50) 1.0 
a CMV: Cytomegalovirus, Hib: Haemophilus influenzae type b, MCV: Meningococcal conjugate 8 
vaccine, PPS6: Phospho-p70 S6 Kinase, PPSV23: nonconjugated polysaccharide, Pneumovax 23-9 
valent vaccines.  10 
b These four patients had defective isohemagglutinins tests and therefore, according to the criteria of 11 
the European Society for Immunodeficiencies (ESID), they have a diagnosis of CVID.  12 
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Table S2- Medical manifestations and clinical phenotypes of 48 patients with CVID at diagnosis 13 
including 8 responders and 40 non-responders to A(H1N1) pandemic vaccine. 14 
Parameters Total CVID 
 
Numbers (%) 
Responders to  
Pandemrix® 
Numbers (%) 
Non-responders 
to Pandemrix® 
Numbers (%)  
p-value* 
Medical manifestations 
Recurrent upper respiratory tract infections 48(100) 8(100) 40(100) 1 
Lower respiratory tract infections 44 5(62.5) 33(82.5) 0.20 
Bronchiectasis 7(14.5) 0 7(17.5) 0.10 
Autoimmune cytopenia 5(10.4) 0 5(12.5) 0.29 
Inflammatory bowel diseases 6(12.5) 1(12.5) 5(12.5) 1 
Celiac disease 4(8.3) 1(12.5) 3(7.5) 0.64 
Psoriasis 3(6.2) 0 3(7.5) 0.42 
Vitiligo 2(4.1) 0 2(5) 0.51 
Diabetes mellitus type 1 2(4.1) 0 2(5) 0.51 
Systemic lupus erythematosus 1(2.1) 1(12.5) 1(2.5) 0.19 
Waldeyer's lymphadenopathy 5(10.4) 1(12.5) 4(10) 0.83 
Generalized lymphadenopathy 4(8.3) 0 4(10) 0.35 
Splenomegaly 2(4.1) 0 2(5) 0.51 
Granulomatous disease 1(2.1) 0 1(2.5) 0.65 
Malignancies 14(29.1) 2(25) 12(30)  0.38 
Breast cancer 2(4.1) 1(12.5) 1(2.5) 0.19 
Colon cancer 2(4.1) 1(12.5) 1(2.5) 0.19 
Thymoma/lymphoma 9(12.5) 0 9(22.5) 0.13 
Prostate cancer 1(2.1) 0 1(2.5) 0.65 
IgE mediated atopic disorders 13(27.1) 4(50) 9(22.5) 0.12 
Asthma 4(8.3) 0 4(10) 0.35 
Clinical phenotypes 
Infections without any other disease-related 
complications 
14(29.1) 1(12.5) 13(32.5) 0.12 
Autoimmunity phenotype 14(29.1) 2(25) 12(30) 0.38 
Enteropathy phenotype 4(8.3) 4(50) 0 <0.001 
Polyclonal lymphocytic infiltration 
phenotype 
3(6.2)  0 3(7.5) 0.42 
Overlapping phenotypes 13(27.0) 1(12.5) 12(30) 0.30 
* p values <0.05 were regarded signiﬁcant and are bolded 15 
